Narodowy Instytut Leków-ko ikertzaileekin lankidetzan egindako argitalpenak (12)

2019

  1. Capillary Nano-immunoassay for Quantification of Proteins from CD138-purified Myeloma Cells

    Bio-protocol, Vol. 9, Núm. 12

  2. Factors regulating microRNA expression and function in multiple myeloma

    Non-coding RNA, Vol. 5, Núm. 1

  3. Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background

    Blood Cancer Journal, Vol. 9, Núm. 12

2018

  1. A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: Biological and clinical utility

    Haematologica, Vol. 103, Núm. 5, pp. 880-889

2017

  1. Amiloride, an old diuretic drug, is a potential therapeutic agent for multiple myeloma

    Clinical Cancer Research, Vol. 23, Núm. 21, pp. 6602-6615

  2. DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma

    Journal of Hematology and Oncology, Vol. 10, Núm. 1

  3. The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma

    Haematologica, Vol. 102, Núm. 12, pp. 2113-2124

2016

  1. Microvesicles from Mesenchymal Stromal Cells Are Involved in HPC-Microenvironment Crosstalk in Myelodysplastic Patients

    PLoS ONE, Vol. 11, Núm. 2

  2. Molecular mechanisms of p53 deregulation in cancer: An overview in multiple myeloma

    International Journal of Molecular Sciences, Vol. 17, Núm. 12

  3. Post-transcriptional modifications contribute to the upregulation of cyclin D2 in multiple myeloma

    Clinical Cancer Research, Vol. 22, Núm. 1, pp. 207-217

2015

  1. Insights into epigenetic regulation of microRNA-155 expression in multiple myeloma

    Biochimica et Biophysica Acta - Gene Regulatory Mechanisms, Vol. 1849, Núm. 3, pp. 353-366

  2. MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL

    BMC Cancer, Vol. 15, Núm. 1